Drugs / BCT197
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03498170 | Mar → May 2018 | — | Mereo BioPharma | Completed | No outcome recorded |
| Phase 1 | NCT02926326 | Sep → Oct 2016 | — | Mereo BioPharma | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT02700919 | Aug 2016 → Nov 2017 | chronic obstructive pulmonary disease | Mereo BioPharma | Completed | Missed primary |
| Phase 2 | NCT01336959 | Sep 2011 → Nov 2013 | acute kidney injury | Mereo BioPharma | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2017-12-11 | Mereo BioPharma | Results Mereo announces positive top-line results from Phase 2 trial with BCT-197 (acumapimod) mereobiopharma.com ↗
today announces positive top-line data from a Phase 2 clinical trial with BCT-197 (acumapimod), a novel, orally active p38 MAP kinase inhibitor in development as a first-line therapy for acute exacerbations of chronic obstructive pulmonary disease (AECOPD). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-12-11 | Mereo BioPharma | Mereo announces positive top-line results from Phase 2 trial with BCT-197 (acumapimod) mereobiopharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCT197 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02700919 ↗ |
| Route | Oral | “Capsules will be taken orally with fluids over a 5 day period after randomization” NCT02700919 ↗ |